S&P 500   4,667.98 (+1.60%)
DOW   35,236.56 (+0.97%)
QQQ   400.03 (+2.26%)
AAPL   160.59 (+2.41%)
MSFT   337.95 (+2.51%)
FB   338.81 (+1.71%)
GOOGL   2,913.94 (+2.47%)
AMZN   3,588.40 (+2.39%)
TSLA   1,140.49 (+5.41%)
NVDA   329.61 (+4.63%)
BABA   131.95 (-1.05%)
NIO   40.28 (+0.73%)
CGC   11.13 (-4.79%)
AMD   159.99 (+3.35%)
GE   98.89 (+1.07%)
MU   85.18 (+2.11%)
T   24.02 (-0.83%)
F   19.86 (+0.56%)
DIS   147.61 (-0.34%)
ACB   6.50 (-4.27%)
AMC   37.16 (-1.25%)
PFE   53.84 (-0.30%)
BA   198.88 (-0.17%)
S&P 500   4,667.98 (+1.60%)
DOW   35,236.56 (+0.97%)
QQQ   400.03 (+2.26%)
AAPL   160.59 (+2.41%)
MSFT   337.95 (+2.51%)
FB   338.81 (+1.71%)
GOOGL   2,913.94 (+2.47%)
AMZN   3,588.40 (+2.39%)
TSLA   1,140.49 (+5.41%)
NVDA   329.61 (+4.63%)
BABA   131.95 (-1.05%)
NIO   40.28 (+0.73%)
CGC   11.13 (-4.79%)
AMD   159.99 (+3.35%)
GE   98.89 (+1.07%)
MU   85.18 (+2.11%)
T   24.02 (-0.83%)
F   19.86 (+0.56%)
DIS   147.61 (-0.34%)
ACB   6.50 (-4.27%)
AMC   37.16 (-1.25%)
PFE   53.84 (-0.30%)
BA   198.88 (-0.17%)
S&P 500   4,667.98 (+1.60%)
DOW   35,236.56 (+0.97%)
QQQ   400.03 (+2.26%)
AAPL   160.59 (+2.41%)
MSFT   337.95 (+2.51%)
FB   338.81 (+1.71%)
GOOGL   2,913.94 (+2.47%)
AMZN   3,588.40 (+2.39%)
TSLA   1,140.49 (+5.41%)
NVDA   329.61 (+4.63%)
BABA   131.95 (-1.05%)
NIO   40.28 (+0.73%)
CGC   11.13 (-4.79%)
AMD   159.99 (+3.35%)
GE   98.89 (+1.07%)
MU   85.18 (+2.11%)
T   24.02 (-0.83%)
F   19.86 (+0.56%)
DIS   147.61 (-0.34%)
ACB   6.50 (-4.27%)
AMC   37.16 (-1.25%)
PFE   53.84 (-0.30%)
BA   198.88 (-0.17%)
S&P 500   4,667.98 (+1.60%)
DOW   35,236.56 (+0.97%)
QQQ   400.03 (+2.26%)
AAPL   160.59 (+2.41%)
MSFT   337.95 (+2.51%)
FB   338.81 (+1.71%)
GOOGL   2,913.94 (+2.47%)
AMZN   3,588.40 (+2.39%)
TSLA   1,140.49 (+5.41%)
NVDA   329.61 (+4.63%)
BABA   131.95 (-1.05%)
NIO   40.28 (+0.73%)
CGC   11.13 (-4.79%)
AMD   159.99 (+3.35%)
GE   98.89 (+1.07%)
MU   85.18 (+2.11%)
T   24.02 (-0.83%)
F   19.86 (+0.56%)
DIS   147.61 (-0.34%)
ACB   6.50 (-4.27%)
AMC   37.16 (-1.25%)
PFE   53.84 (-0.30%)
BA   198.88 (-0.17%)
NASDAQ:ASND

Ascendis Pharma A/S Stock Forecast, Price & News

$143.04
-0.78 (-0.54%)
(As of 11/29/2021 01:02 PM ET)
Add
Compare
Today's Range
$142.52
$146.82
50-Day Range
$139.74
$169.66
52-Week Range
$109.36
$183.98
Volume
1,211 shs
Average Volume
217,445 shs
Market Capitalization
$8.14 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.72
30 days | 90 days | 365 days | Advanced Chart
Receive ASND News and Ratings via Email

Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.


Ascendis Pharma A/S logo

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.

Headlines

Analyst Ratings For Ascendis Pharma
November 11, 2021 |  markets.businessinsider.com
Ascendis Pharma A/S (ASND) Q3 2021 Earnings Call Transcript
November 10, 2021 |  finance.yahoo.com
Ascendis Pharma (spons ADRs) earnings: here's what Wall Street expects
November 10, 2021 |  markets.businessinsider.com
Were Hedge Funds Right About Ascendis Pharma A/S (ASND)?
November 10, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ASND
Employees
2,020
Year Founded
N/A

Sales & Book Value

Annual Sales
$7.94 million
Book Value
$20.60 per share

Profitability

Net Income
$-478.57 million
Net Margins
-12,211.21%
Pretax Margin
-12,130.59%

Debt

Price-To-Earnings

Miscellaneous

Free Float
34,127,000
Market Cap
$8.14 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/09/2021
Today
11/29/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/09/2022

MarketRank

Overall MarketRank

2.28 out of 5 stars

Medical Sector

299th out of 1,392 stocks

Pharmaceutical Preparations Industry

131st out of 670 stocks

Analyst Opinion: 3.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












Ascendis Pharma A/S (NASDAQ:ASND) Frequently Asked Questions

Is Ascendis Pharma A/S a buy right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Ascendis Pharma A/S stock.
View analyst ratings for Ascendis Pharma A/S
or view top-rated stocks.

How has Ascendis Pharma A/S's stock price been impacted by Coronavirus?

Ascendis Pharma A/S's stock was trading at $118.53 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ASND stock has increased by 20.8% and is now trading at $143.15.
View which stocks have been most impacted by COVID-19
.

When is Ascendis Pharma A/S's next earnings date?

Ascendis Pharma A/S is scheduled to release its next quarterly earnings announcement on Wednesday, March 9th 2022.
View our earnings forecast for Ascendis Pharma A/S
.

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) posted its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported ($1.47) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($2.60) by $1.13. Ascendis Pharma A/S had a negative net margin of 12,211.21% and a negative trailing twelve-month return on equity of 50.72%. During the same quarter in the previous year, the firm posted ($2.70) earnings per share.
View Ascendis Pharma A/S's earnings history
.

What price target have analysts set for ASND?

11 analysts have issued 12 month price targets for Ascendis Pharma A/S's shares. Their forecasts range from $169.00 to $216.00. On average, they expect Ascendis Pharma A/S's share price to reach $189.50 in the next year. This suggests a possible upside of 32.4% from the stock's current price.
View analysts' price targets for Ascendis Pharma A/S
or view top-rated stocks among Wall Street analysts.

Who are Ascendis Pharma A/S's key executives?

Ascendis Pharma A/S's management team includes the following people:
  • Jan Møller Mikkelsen, President, CEO & Executive Director
  • Scott Thomas Smith, Chief Financial Officer & Senior Vice President
  • Kennett Sprogøe, Senior Vice President, Head-Innovation & Research
  • Birgitte Volck, SVP, Head-Clinical Development & Medical Affairs
  • Lotte Sønderbjerg, Chief Administrative Officer & Senior VP

What other stocks do shareholders of Ascendis Pharma A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Neurocrine Biosciences (NBIX), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (bmrn), Gilead Sciences (GILD), Incyte (INCY), Exelixis (EXEL), GW Pharmaceuticals (GWPH) and NVIDIA (NVDA).

When did Ascendis Pharma A/S IPO?

(ASND) raised $85 million in an IPO on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager.

What is Ascendis Pharma A/S's stock symbol?

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

Who are Ascendis Pharma A/S's major shareholders?

Ascendis Pharma A/S's stock is owned by a variety of institutional and retail investors. Top institutional investors include Artisan Partners Limited Partnership (13.71%), RA Capital Management L.P. (13.01%), Wellington Management Group LLP (6.95%), Janus Henderson Group PLC (5.73%), Spyglass Capital Management LLC (2.43%) and Invesco Ltd. (1.81%).

Which major investors are selling Ascendis Pharma A/S stock?

ASND stock was sold by a variety of institutional investors in the last quarter, including Caption Management LLC, FIL Ltd, Invesco Ltd., Goldman Sachs Group Inc., Candriam Luxembourg S.C.A., Thrivent Financial for Lutherans, Alliancebernstein L.P., and Bank of New York Mellon Corp.

Which major investors are buying Ascendis Pharma A/S stock?

ASND stock was bought by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, RA Capital Management L.P., Wellington Management Group LLP, Spyglass Capital Management LLC, TimesSquare Capital Management LLC, Eversept Partners LP, Rock Springs Capital Management LP, and Deutsche Bank AG.

How do I buy shares of Ascendis Pharma A/S?

Shares of ASND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ascendis Pharma A/S's stock price today?

One share of ASND stock can currently be purchased for approximately $143.15.

How much money does Ascendis Pharma A/S make?

Ascendis Pharma A/S has a market capitalization of $8.14 billion and generates $7.94 million in revenue each year. The biotechnology company earns $-478.57 million in net income (profit) each year or ($9.30) on an earnings per share basis.

How many employees does Ascendis Pharma A/S have?

Ascendis Pharma A/S employs 2,020 workers across the globe.

What is Ascendis Pharma A/S's official website?

The official website for Ascendis Pharma A/S is www.ascendispharma.com.

Where are Ascendis Pharma A/S's headquarters?

Ascendis Pharma A/S is headquartered at TUBORG BOULEVARD 12, HELLERUP G7, DK-2900.

How can I contact Ascendis Pharma A/S?

Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The biotechnology company can be reached via phone at (457) 022-2244, via email at [email protected], or via fax at 45-3694-4010.


This page was last updated on 11/29/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.